– VYLOY is the first and only CLDN18.2-targeted treatment approved in the India for adult patients with HER2 negative gastric and gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2 positive – – Central Drugs Standard Control Organization approval was based on the global Phase 3 trials GLOW & SPOTLIGHT where the combination treatment extended median overall survival …



